Celyad received a letter on March 31 from Nasdaq informing the company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450 for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYAD:
- Celyad Oncology announces receipt of Nasdaq notice
- Celyad names Georges Rawadi as new CEO
- Celyad Oncology appoints Georges Rawadi as its new CEO
- Celyad Oncology reports full year 2022 financial results and recent business highlights
- Celyad Oncology to announce full year 2022 financial results and host conference call
